Intra-Cellular ticks higher as J&J forecasts early Q2 close
by Contributor since / Followers
2 months ago
JHVEPhoto
Intra-Cellular Therapies (NASDAQ:ITCI) edged higher by 0.6% as Johnson & Johnson (JNJ) said it expects its planned more than $14 billion acquisition to close early in the second quarter.
Johnson & Johnson (JNJ) made the early Q2 forecast on
